Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT ID: NCT00368108
Last Updated: 2013-05-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
752 participants
INTERVENTIONAL
2006-08-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00286897
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00360308
A Study of E2007 In Patients With Parkinson's Disease
NCT00427011
Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
NCT01634360
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
NCT00165789
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2 mg perampanel
The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
2 mg perampanel
2 mg perampanel
4 mg perampanel
The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
4 mg perampanel
4 mg perampanel
placebo
The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
placebo comparator
placebo comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2 mg perampanel
2 mg perampanel
4 mg perampanel
4 mg perampanel
placebo comparator
placebo comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have been diagnosed with idiopathic PD at \> 30 years of age.
3. Patients must have predictable motor fluctuations of the wearing "OFF" type.
4. Patients must rate between II-IV on the Hoehn \& Yahr scale when in an "OFF" state.
5. Patients must be taking optimized levodopa therapy.
Exclusion Criteria
2. Women of child bearing potential unless infertile (including surgically sterile) or practicing effective contraception (eg, abstinence, intrauterine device or barrier method plus hormonal method). These patients must have a negative serum beta-human chorionic gonadotrophin (B-HCG) test at the Screening visit, and a negative urine pregnancy test at the Baseline visit (Day 0). These patients must also be willing to remain on their current form of contraception for the duration of the study. Postmenopausal women may be recruited but must be amenorrheic for at least one year to be considered of non-child bearing potential as determined by the Investigator.
3. Patients with a past or present history of drug or alcohol abuse as per Diagnostic and Statistical Manual - 4th edition (DSM IV) criteria.
4. Patients with a past (within one year) or present history of suicidal ideation or suicide attempts.
5. Patients with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, gastro-intestinal, hematological, endocrine or metabolic systems which might complicate assessment of the tolerability of the study medication.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Squillacote, M.D.
Role: STUDY_DIRECTOR
Eisai Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
North Alabama Neuroscience Research Associates
Huntsville, Alabama, United States
Pivotal Research Centers
Peoria, Arizona, United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Clinical Trials Inc.
Little Rock, Arkansas, United States
UAMS Department of Neurology
Little Rock, Arkansas, United States
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States
Margolin Brain Institute
Fresno, California, United States
University of California Medical Center - Irvine
Irvine, California, United States
Coastal Neurological Group
La Jolla, California, United States
Scripps Clinic
La Jolla, California, United States
University of California at San Diego - Department of Neurology
La Jolla, California, United States
Loma Linda University
Loma Linda, California, United States
University of Southern California
Los Angeles, California, United States
Pacific Neuroscience Medical Group, Inc.
Oxnard, California, United States
University of California San Francisco Medical Center
San Francisco, California, United States
The Parkinson's Institute
Sunnyvale, California, United States
Mile High Research Center
Denver, Colorado, United States
University Of Colorado
Denver, Colorado, United States
Colorado Neurology
Englewood, Colorado, United States
Associated Neurologists, PC - Danbury
Danbury, Connecticut, United States
Hartford Hospital
Hartford, Connecticut, United States
Molecular Neuroimaging, LLC
New Haven, Connecticut, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Parkinson's Disease and Movement Disorder Center of Boca Raton
Boca Raton, Florida, United States
Brain Matters Research
Delray Beach, Florida, United States
University of Florida
Gainesville, Florida, United States
Sunrise Clinical Research
Hollywood, Florida, United States
University of Florida - Department of Neurology
Jacksonville, Florida, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Miami Research Associates
Miami, Florida, United States
Palm Beach Neurological Center
Palm Beach Gardens, Florida, United States
Gil, Ramon A.
Port Charlotte, Florida, United States
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States
University Of South Florida Movement Disorders Clinic
Tampa, Florida, United States
Cleveland Clinic Florida - Weston
Weston, Florida, United States
Emory University
Atlanta, Georgia, United States
Medical College of Georgia
Augusta, Georgia, United States
Dekalb Neurology Associates, LLC/DNA Research
Decatur, Georgia, United States
Northwestern University Medical School
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
OSF Saint Francis Medical Center
Peoria, Illinois, United States
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Indiana University
Indianapolis, Indiana, United States
University Of Iowa
Iowa City, Iowa, United States
University of Kansas
Kansas City, Kansas, United States
University Of Kentucky
Lexington, Kentucky, United States
Kentucky Neuroscience Research
Louisville, Kentucky, United States
LSUHSC-Shreveport
Shreveport, Louisiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Parkinson's and Movement Disorders Center of Maryland
Elkridge, Maryland, United States
Boston University Medical Center
Boston, Massachusetts, United States
Harvard Vanguard Medical Associates
Boston, Massachusetts, United States
Quest Research Institute
Bingham Farms, Michigan, United States
The Clinical Neurosciences Center
Southfield, Michigan, United States
Northern Michigan Neurology
Traverse City, Michigan, United States
Struthers Parkinson's Center
Golden Valley, Minnesota, United States
University of Minnesota
Minneapolis, Minnesota, United States
Washington University
St Louis, Missouri, United States
Creighton University - Department of Neurology
Omaha, Nebraska, United States
University of Nevada School of Medicine
Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
University of Medicine and Dentistry of New Jersey
New Brunswick, New Jersey, United States
Albany Medical College
Albany, New York, United States
Parkinson's Disease and Movement Disorder Center of Long Island
Commack, New York, United States
New York University Medical Center
Forest Hills, New York, United States
North Shore Medical Center
Manhasset, New York, United States
The Mount Sinai Medical Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Columbia University
New York, New York, United States
University of Rochester - Neurology Clinic
Rochester, New York, United States
Asheville Neurology Specialists. PA
Asheville, North Carolina, United States
Asheville Neurology Specialists
Asheville, North Carolina, United States
Duke University
Durham, North Carolina, United States
Raleigh Neurology Associates, P.A.
Raleigh, North Carolina, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Neurology Specialists, Inc.
Dayton, Ohio, United States
The University of Toledo College of Medicine
Toledo, Ohio, United States
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Crozer Medical Center
Upland, Pennsylvania, United States
Lankenau Hospital
Wynnewood, Pennsylvania, United States
Semmes Murphey Neurology and Spine Institute
Memphis, Tennessee, United States
Radiant Research - Dallas North
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Agape' Medical Center, Inc.
Lubbock, Texas, United States
Bhupesh Dihenia, MD, PA
Lubbock, Texas, United States
Neurology Associates
San Antonio, Texas, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
Hunter Holmes McGuire
Richmond, Virginia, United States
Neurology and Neurosurgery Associates of Tacoma, PLLC
Tacoma, Washington, United States
Capitol Neurology
Charleston, West Virginia, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Wisconsin Institute for Neurologic and Sleep Disorders
Milwaukee, Wisconsin, United States
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Pacific Parkinson Research Centre
Vancouver, British Columbia, Canada
Saint John Regional Hospital, 5DN
Saint John, New Brunswick, Canada
David King, MD
Halifax, Nova Scotia, Canada
Centre For Movement Disorders
Markham, Ontario, Canada
Parkinson's and Neurodegenerative Disorders Clinic
Ottawa, Ontario, Canada
The Ottawa Hospital - Civic Campus
Ottawa, Ontario, Canada
Torotnto Western Hospital-University Health Network
Toronto, Ontario, Canada
Clinique Neuro Rive-Sud
Greenfield Park, Quebec, Canada
CHUM- Hotel-Dieu
Montreal, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada
SMBD Jewish General Hospital
Montreal, Quebec, Canada
Quebec Memory and Motor Skills Disorders Clinic
Québec, Quebec, Canada
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2007-A001-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.